Avastin meets goal in first Phase III trial in ovarian cancer
25 February 2010
Malini Guha
Please Login to read the full article.
25 February 2010
Malini Guha
The first Phase III trial of Roche's Avastin (bevacizumab) in previously untreated advanced ovarian cancer has shown that the anti-angiogenic monoclonal antibody drug has improved progression-free survival (PFS) when used for a longer duration, but not a shorter duration of therapy.
The...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod
- Peregrine flies with positive Phase II bavituximab lung cancer data
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Merck Serono again tries to FLEX Erbitux's muscle in NSCLC
ANALYSIS
Other Informa Analysis
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
